Inclusion Criteria:

- The patients with gallbladder and bile duct cancer diagnosis by surgical exploration,
or intraoperative frozen biopsy (Annex 2).

- Aged 18 to 70 years old, male or female, body condition score generally ECOG 0～2,
expected survival ≥ 3 months.

- Subjects were no major organ dysfunction, blood, liver, kidney and heart function was
normal, the specific requirements of laboratory indicators:

Blood: WBC count > 3.0 × 109 / L, Platelet count> 100 × 109 / L, Hb > 8.0g/dl. Liver
function：serum bilirubin less than 1.5 times the upper limit of normal; ALT and AST less
than 3 times the upper limit of normal.

Renal function: creatinine less than 1.5 times the upper limit of normal.

- Participants have used other chemotherapy drugs, subject to the 30-day washout period
before proceeding with the test.

- Patients had no anaphylactic reaction with oxaliplatin and fluorouracil in the past.

- Patients who can understand the circumstances of this study and signed informed
consent.

Exclusion Criteria:

- Currently is receiving effective treatment；

- Pregnancy, breast-feeding patients；

- Primary brain tumors or central nervous system metastatic tumor is not controlled;

- Patients received chemotherapy, radiotherapy, biological therapy, other drugs or
instrument therapy 30 days before enrollment.

- Patients with purulent and chronic infected wounds which delayed healing.

- Patients with liver, kidney and heart failure and coronary heart disease, angina,
myocardial infarction, arrhythmia, cerebral thrombosis, stroke and other serious
cardiovascular and cerebrovascular disease;

- Patients has a history of mental illness and difficult to control;

- Patients who was considered inappropriate to participate in the trials by the
researchers.